Stay updated with breaking news from Farhad parhami. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MAX BioPharma Announces Publication of Proof of Principle Regarding its Oxysterol Lead Drug Candidate, Oxy210 that Inhibits Fatty Liver and Fibrosis in a Humanized Mouse Model prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Reply A biopharmaceutical startup helmed in Santa Monica has produced a new drug candidate to treat coronavirus with antiviral activity. (Shutterstock) SANTA MONICA, CA A biopharmaceutical startup helmed in Santa Monica has produced a new drug candidate to treat coronavirus with antiviral activity. MAX BioPharma s product is intended to reduce illness caused by the virus in an infected patient, the Santa Monica Mirror reported. The potential treatment is reportedly made up of semi-synthetic oxysterols, dervied from a collection of sterol molecues created by MaxBioPharma. The drug candidate was created in collaboration with scientists at the National Institute of Infectious Diseases in Tokyo, Japan. ....
Share this article Share this article LOS ANGELES, Feb. 2, 2021 /PRNewswire/ In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma (www.maxbiopharma.com) scientists have identified new substances with antiviral activity against the novel coronavirus, SARS-CoV-2, the virus that caused the ongoing global COVID-19 pandemic (www.biorxiv.org/content/10.1101/2021.01.31.429001v1). These new substances, so-called semi-synthetic oxysterols, were derived from a collection of sterol molecules created by MAX BioPharma, as part of its Oxysterol Therapeutics® platform technology that has produced oxysterol-based drug candidates in other therapeutic indications, including cancer, fibrosis, and bone formation. ....